Jim Xiang

List of Publications by Year in descending order

166 papers	4,875 citations	94433 37 h-index	133252 59 g-index
166 all docs	166 docs citations	166 times ranked	5991 citing authors

#	Article	IF	Citations
1	Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology, 2007, 120, 90-102.	4.4	200
2	Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. International Journal of Cancer, 2001, 93, 539-548.	5.1	151
3	HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer, 2015, 22, 101-116.	2.9	149
4	A New Dynamic Model of CD8+ T Effector Cell Responses via CD4+ T Helper-Antigen-Presenting Cells. Journal of Immunology, 2005, 174, 7497-7505.	0.8	134
5	Membraneâ€bound HSP70â€engineered myeloma cellâ€derived exosomes stimulate more efficient CD8⁺ CTLâ€•and NKâ€mediated antitumour immunity than exosomes released from heatâ€shocked tumour cells expressing cytoplasmic HSP70. Journal of Cellular and Molecular Medicine, 2010, 14, 2655-2666.	3.6	129
6	Mechanisms of cellular communication through intercellular protein transfer. Journal of Cellular and Molecular Medicine, 2011, 15, 1458-1473.	3.6	128
7	Dendritic Cells Recruit T Cell Exosomes via Exosomal LFA-1 Leading to Inhibition of CD8+ CTL Responses through Downregulation of Peptide/MHC Class I and Fas Ligand-Mediated Cytotoxicity. Journal of Immunology, 2010, 185, 5268-5278.	0.8	106
8	Intercellular Trogocytosis Plays an Important Role in Modulation of Immune Responses. Cellular and Molecular Immunology, 2008, 5, 261-269.	10.5	102
9	CD4+ T cell-released exosomes inhibit CD8+ cytotoxic T-lymphocyte responses and antitumor immunity. Cellular and Molecular Immunology, 2011, 8, 23-30.	10.5	97
10	Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. International Journal of Molecular Sciences, 2020, 21, 9123.	4.1	91
11	Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cellular and Molecular Immunology, 2006, 3, 205-11.	10.5	91
12	Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. International Journal of Molecular Sciences, 2020, 21, 2793.	4.1	89
13	Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunology, Immunotherapy, 2011, 60, 1473-1484.	4.2	81
14	CD4+Th1 cells promote CD8+Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology, 2007, 120, 148-159.	4.4	77
15	One Hundred Seventy-Fold Increase in Excretion of an FV Fragment-Tumor Necrosis Factor Alpha Fusion Protein (sFV/TNF-Î±) from Escherichia coli Caused by the Synergistic Effects of Glycine and Triton X-100. Applied and Environmental Microbiology, 1998, 64, 2869-2874.	3.1	71
16	Natural CD8+25+ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma. Biochemical and Biophysical Research Communications, 2013, 438, 152-155.	2.1	71
17	Lymphotactin Expression by Engineered Myeloma Cells Drives Tumor Regression: Mediation by CD4+ and CD8+ T Cells and Neutrophils Expressing XCR1 Receptor. Journal of Immunology, 2001, 167, 57-65.	0.8	64
18	Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Letters, 2008, 271, 105-116.	7.2	62

#	Article	IF	Citations
19	CD4â˜'8â˜' Dendritic Cells Prime CD4+ T Regulatory 1 Cells to Suppress Antitumor Immunity. Journal of Immunology, 2005, 175, 2931-2937.	0.8	61
20	Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leukemia Research, 2002, 26, 757-763.	0.8	59
21	Simulated microgravity inhibits cell focal adhesions leading to reduced melanoma cell proliferation and metastasis via FAK/RhoA-regulated mTORC1 and AMPK pathways. Scientific Reports, 2018, 8, 3769.	3.3	59
22	Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. Cellular and Molecular Immunology, 2007, 4, 105-11.	10.5	57
23	Neutrophils and B Cells Express XCR1 Receptor and Chemotactically Respond to Lymphotactin. Biochemical and Biophysical Research Communications, 2001, 281, 378-382.	2.1	56
24	Analysis of the Gene Expression Profiles of Immature versus Mature Bone Marrow-Derived Dendritic Cells Using DNA Arrays. Biochemical and Biophysical Research Communications, 2002, 290, 66-72.	2.1	56
25	Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology, 2003, 108, 177-188.	4.4	54
26	Review: Cancer Immunotherapy by Exosome-Based Vaccines. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 692-703.	1.0	54
27	CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses. Journal of Immunology, 2009, 182, 193-206.	0.8	53
28	The Spectrum of Neuroendocrine Differentiation Among Gastrointestinal Carcinoids. Archives of Pathology and Laboratory Medicine, 2000, 124, 570-576.	2.5	53
29	Novel Exosome-Targeted CD4+ T Cell Vaccine Counteracting CD4+25+ Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory CD8+ CTL Responses. Journal of Immunology, 2007, 179, 2731-2740.	0.8	51
30	Nonspecific CD4+ T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8+ CTL responses and long-term T cell memory. Journal of Leukocyte Biology, 2007, 82, 829-838.	3.3	51
31	Tumor Apoptotic Bodies Inhibit CTL Responses and Antitumor Immunity via Membrane-Bound Transforming Growth Factor-Î²1 Inducing CD8+ T-Cell Anergy and CD4+ Tr1 Cell Responses. Cancer Research, 2009, 69, 7756-7766.	0.9	50
32	Multiple effects of CD40–CD40L axis in immunity against infection and cancer. ImmunoTargets and Therapy, 2018, Volume 7, 55-61.	5.8	50
33	Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Research, 2002, 62, 2043-51.	0.9	48
34	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. Cancer Gene Therapy, 2002, 9, 202-208.	4.6	44
35	CD8Î±+, but Not CD8Î±â˜', Dendritic Cells Tolerize Th2 Responses via Contact-Dependent and -Independent Mechanisms, and Reverse Airway Hyperresponsiveness, Th2, and Eosinophil Responses in a Mouse Model of Asthma. Journal of Immunology, 2005, 175, 1516-1522.	0.8	43
36	Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Therapy, 2002, 9, 533-542.	4.6	40

#	Article	IF	Citations
37	DNA Array and Biological Characterization of the Impact of the Maturation Status of Mouse Dendritic Cells on Their Phenotype and Antitumor Vaccination Efficacy. Cellular Immunology, 2001, 214, 60-71.	3.0	39
38	CD8+ Cytotoxic T-APC Stimulate Central Memory CD8+ T Cell Responses via Acquired Peptide-MHC Class I Complexes and CD80 Costimulation, and IL-2 Secretion. Journal of Immunology, 2006, 177, 2976-2984.	0.8	39
39	GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+ T-independent CTL responses. Vaccine, 2011, 29, 3538-3547.	3.8	39
40	Bidirectional membrane molecule transfer between dendritic and T cells. Biochemical and Biophysical Research Communications, 2007, 359, 202-208.	2.1	37
41	Disrupted RabGAP Function of the p85 Subunit of Phosphatidylinositol 3-Kinase Results in Cell Transformation. Journal of Biological Chemistry, 2008, 283, 15861-15868.	3.4	37
42	Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice. Breast Cancer Research and Treatment, 2013, 140, 273-284.	2.5	37
43	Simulated Microgravity Reduces Focal Adhesions and Alters Cytoskeleton and Nuclear Positioning Leading to Enhanced Apoptosis via Suppressing FAK/RhoA-Mediated mTORC1/NF-Î²B and ERK1/2 Pathways. International Journal of Molecular Sciences, 2018, 19, 1994.	4.1	37
44	TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasisÂ. Cellular and Molecular Immunology, 2019, 16, 820-832.	10.5	37
45	IL-10 Has A Distinct Immunoregulatory Effect on Naive and Active T Cell Subsets. Journal of Interferon and Cytokine Research, 2007, 27, 1031-1038.	1.2	36
46	Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Research, 2006, 16, 241-259.	12.0	35
47	Adenovirus-Mediated ING4 Expression Suppresses Pancreatic Carcinoma Cell Growth via Induction of Cell-Cycle Alteration, Apoptosis, and Inhibition of Tumor Angiogenesis. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 261-269.	1.0	35
48	Adenovirus-mediated TNF-Î± Gene Transfer induces Significant Tumor Regression in Mice. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 49-57.	1.0	34
49	Synergistic effect of adoptive T-cell therapy and intratumoral interferon Î³-inducible protein-10 transgene expression in treatment of established tumors. Cellular Immunology, 2002, 217, 12-22.	3.0	34
50	Framework Residues 71 and 93 of the Chimeric B72.3 Antibody are Major Determinants of the Conformation of Heavy-chain Hypervariable Loops. Journal of Molecular Biology, 1995, 253, 385-390.	4.2	33
51	Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Therapy, 2002, 9, 778-786.	4.6	33
52	Engineered Fusion Hybrid Vaccine of IL-18 Gene-Modified Tumor Cells and Dendritic Cells Induces Enhanced Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 322-330.	1.0	32
53	Simulated Microgravity Promotes Cell Apoptosis Through Suppressing Uev1A/TICAM/TRAF/NFâ€Îºâ€Regulated Antiâ€Apoptosis and p53/PCNAâ€•and ATM/ATRâ€Chk1/2â€Controlled DNAâ€Damage Response Pathways. Journal of Cellular Biochemistry, 2016, 117, 2138-2148.	3.2	32
54	IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. Cell and Bioscience, 2016, 6, 30.	4.8	32

#	Article	IF	Citations
55	DNA microarray analysis of the gene expression profiles of naÄ±Ì^ve versus activated tumor-specific T cells. Life Sciences, 2002, 71, 3005-3017.	4.3	31
56	Synergistic effect of lymphotactin and interferon ?-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. International Journal of Cancer, 2004, 109, 817-825.	5.1	30
57	Tumor-Infiltrating Dendritic Cell Subsets of Progressive or Regressive Tumors Induce Suppressive or Protective Immune Responses. Cancer Research, 2005, 65, 4955-4962.	0.9	30
58	A Distinct Role of CD4+ Th17- and Th17-Stimulated CD8+ CTL in the Pathogenesis of Type 1 Diabetes and Experimental Autoimmune Encephalomyelitis. Journal of Clinical Immunology, 2011, 31, 811-826.	3.8	30
59	Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. Cellular and Molecular Immunology, 2017, 14, 529-545.	10.5	30
60	A genetically engineered single-chain FVTNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor. Molecular Immunology, 1995, 32, 873-881.	2.2	29
61	A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling. Cellular and Molecular Immunology, 2013, 10, 72-77.	10.5	29
62	Advances in Dendritic Cell-Based Vaccine of Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 601-619.	1.0	28
63	Regression of Engineered Tumor Cells Secreting Cytokines Is Related to a Shift in Host Cytokine Profile from Type 2 to Type 1. Journal of Interferon and Cytokine Research, 2000, 20, 349-354.	1.2	27
64	Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer. Current Gene Therapy, 2005, 5, 237-247.	2.0	27
65	CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. Journal of Leukocyte Biology, 2006, 80, 1354-1363.	3.3	27
66	Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. Journal of Leukocyte Biology, 2012, 92, 289-300.	3.3	27
67	Novel EXO-T vaccine using polyclonal CD4⁺ T cells armed with HER2-specific exosomes for HER2-positive breast cancer. OncoTargets and Therapy, 2018, Volume 11, 7089-7093.	2.0	27
68	Recombinant Human IL-24 Suppresses Lung Carcinoma Cell Growth via Induction of Cell Apoptosis and Inhibition of Tumor Angiogenesis. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 310-320.	1.0	26
69	Tumor Necrosis Factor Gene-Engineered J558 Tumor Cellâ€“Released Exosomes Stimulate Tumor Antigen P1A-Specific CD8⁺CTL Responses and Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 21-28.	1.0	26
70	Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Therapy, 2005, 12, 122-132.	4.6	25
71	Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice. Vaccine, 2012, 30, 3519-3525.	3.8	25
72	Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis. Journal of Gene Medicine, 2005, 7, 506-517.	2.8	24

#	Article	IF	Citations
73	CD4+ T cell acquisition of the bystander pMHC I colocalizing in the same immunological synapse comprising pMHC II and costimulatory CD40, CD54, CD80, OX40L, and 41BBL. Biochemical and Biophysical Research Communications, 2007, 362, 822-828.	2.1	24
74	Recombinant Human Interleukin-24 Suppresses Gastric Carcinoma Cell GrowthIn VitroandIn Vivo. Cancer Investigation, 2010, 28, 85-93.	1.3	23
75	Synergistic Tumor Suppression by Adenovirus-Mediated Inhibitor of Growth 4 and Interleukin-24 Gene Cotransfer in Hepatocarcinoma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 681-695.	1.0	22
76	Differential expression of mannose-6-phosphate receptor regulates T cell contraction. Journal of Leukocyte Biology, 2015, 98, 313-318.	3.3	22
77	Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Experimental Oncology, 2004, 26, 300-6.	0.1	22
78	Genetic engineering of a recombinant fusion possessing anti-tumor F(abâ€²)2 and tumor necrosis factor. Journal of Biotechnology, 1997, 53, 3-12.	3.8	21
79	Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Therapy, 2000, 7, 1270-1278.	4.6	21
80	Tumor-Suppressive Effect of Adenovirus-Mediated Inhibitor of Growth 4 Gene Transfer in Breast Carcinoma Cells In Vitro and In Vivo. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 427-437.	1.0	21
81	Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Journal of Gene Medicine, 2003, 5, 668-680.	2.8	20
82	Intradermal Vaccination of Dendritic Cellâ€“Derived Exosomes Is Superior to a Subcutaneous One in the Induction of Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 146-154.	1.0	20
83	Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses. Journal of Leukocyte Biology, 2010, 88, 393-403.	3.3	20
84	In Vitro Activation of CD8 Interphotoreceptor Retinoid-Binding Protein-Specific T Cells Requires not only Antigenic Stimulation but also Exogenous Growth Factors. Journal of Immunology, 2006, 176, 5006-5014.	0.8	19
85	Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice. Vaccine, 2018, 36, 1414-1422.	3.8	19
86	Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Therapy, 2000, 7, 1023-1033.	4.6	18
87	Regression of engineered myeloma cells secreting interferon-Î³-inducing factor is mediated by both CD4+/CD8+ T and natural killer cells. Leukemia Research, 2001, 25, 909-915.	0.8	18
88	CpG-Containing Oligodeoxynucleotide 1826 Converts the Weak Uveitogenic Rat Interphotoreceptor Retinoid-Binding Protein Peptide 1181â€“1191 into a Strong Uveitogen. Journal of Immunology, 2003, 171, 4780-4785.	0.8	18
89	Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cellular and Molecular Immunology, 2007, 4, 277-85.	10.5	18
90	Antigen Specificity Acquisition of Adoptive CD4+ Regulatory T Cells via Acquired Peptide-MHC Class I Complexes. Journal of Immunology, 2008, 181, 2428-2437.	0.8	17

#	Article	IF	Citations
91	CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene. Molecular Immunology, 2012, 51, 143-149.	2.2	17
92	mTORC1 regulates mannose-6-phosphate receptor transport and T-cell vulnerability to regulatory T cells by controlling kinesin KIF13A. Cell Discovery, 2017, 3, 17011.	6.7	17
93	Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors. Cellular and Molecular Immunology, 2021, 18, 2632-2647.	10.5	17
94	Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. Journal of Gene Medicine, 2004, 6, 857-868.	2.8	16
95	Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44+CD62Lhigh IL-7R+ CTLs with up- and downregulation of anti- and pro-apoptosis genes. Cellular and Molecular Immunology, 2015, 12, 456-465.	10.5	16
96	Mannose-6-phosphate receptor: a novel regulator of T cell immunity. Cellular and Molecular Immunology, 2018, 15, 986-988.	10.5	16
97	Adenovirus-Mediated Il-24 Expression Suppresses Hepatocellular Carcinoma Growth via Induction of Cell Apoptosis and Cycling Arrest and Reduction of Angiogenesis. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 56-63.	1.0	15
98	Fusion Hybrid of Dendritic Cells and Engineered Tumor Cells Expressing Interleukin-12 Induces Type 1 Immune Responses against Tumor. Tumori, 2005, 91, 531-538.	1.1	14
99	Oncolytic Adenovirus-Mediated E1A Gene Therapy Induces Tumor-Cell Apoptosis and Reduces Tumor Angiogenesis Leading to Inhibition of Hepatocellular Carcinoma Growth in Animal Model. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 225-234.	1.0	14
100	Th Cells Promote CTL Survival and Memory via Acquired pMHC-I and Endogenous IL-2 and CD40L Signaling and by Modulating Apoptosis-Controlling Pathways. PLoS ONE, 2013, 8, e64787.	2.5	13
101	Antitumor Immune Responses Derived from Transgenic Expression of CD40 Ligand in Myeloma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 11-18.	1.0	12
102	Human Dendritic Cells Engineered to Express Alpha Tumor Necrosis Factor Maintain Cellular Maturation and T-Cell Stimulation Capacity. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 613-622.	1.0	12
103	TheIn VitroandIn VivoAntitumor Activity of Adenovirus-Mediated Interleukin-24 Expression for Laryngocarcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 29-38.	1.0	12
104	CD154 and IL-2 Signaling of CD4+ T Cells Play a Critical Role in Multiple Phases of CD8+ CTL Responses Following Adenovirus Vaccination. PLoS ONE, 2012, 7, e47004.	2.5	12
105	Expression of tumor-associated polymorphic epithelial mucin and carcinoembryonic antigen in gastrointestinal carcinoid tumors. Implications for immunodiagnosis and immunotherapy. Cancer, 1995, 75, 2836-2843.	4.1	11
106	Defect of CD8+ Memory T Cells Developed in Absence of IL-12 Priming for Secondary Expansion. Cellular and Molecular Immunology, 2008, 5, 147-152.	10.5	11
107	Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins. Human Antibodies, 1999, 9, 23-36.	1.5	10
108	Acquired pMHC I Complexes Greatly Enhance CD4+ Th Cell's Stimulatory Effect on CD8+ T Cell-Mediated Diabetes in Transgenic RIP-mOVA Mice. Cellular and Molecular Immunology, 2008, 5, 407-415.	10.5	10

#	Article	IF	Citations
109	CD40 ligation converts TGF-Î²-secreting tolerogenic CD4âº8âº dendritic cells into IL-12-secreting immunogenic ones. Biochemical and Biophysical Research Communications, 2009, 379, 954-958.	2.1	10
110	Regulators of Tâ€cell memory generation: TCR signals versus CD4⁺ help?. Immunology and Cell Biology, 2011, 89, 578-580.	2.3	10
111	Differential requirements of <scp>CD</scp>4⁺<scp>T</scp>â€cell signals for effector cytotoxic Tâ€lymphocyte (<scp>CTL</scp>) priming and functional memory <scp>CTL</scp> development at higher <scp>CD</scp>8⁺<scp>T</scp>â€cell precursor frequency. Immunology, 2013, 138, 298-306.	4.4	10
112	HIV-1 Gag-specific exosome-targeted T cell-based vaccine stimulates effector CTL responses leading to therapeutic and long-term immunity against Gag/HLA-A2-expressing B16 melanoma in transgenic HLA-A2 mice. Trials in Vaccinology, 2014, 3, 19-25.	1.2	10
113	Recombinant Bifunctional Molecule FV/IFN-Î³ Possesses the Anti-Tumor FV as Well as the Gamma Interferon Activities. Cancer Biotherapy, 1993, 8, 327-337.	0.5	9
114	Singleâ€chain antibody variable regionâ€targeted interleukinâ€2 stimulates T cell killing of human colorectal carcinoma cells. Immunology and Cell Biology, 1994, 72, 275-285.	2.3	9
115	Identification of a decapeptide with the binding reactivity for tumor-associated TAG72 antigen from a phage displayed library. , 1996, 24, 352-358.		9
116	Mouse Myeloma Cell Line Secreting Bifunctional Fusion Protein RM4/IFN-Ï„ Elicits Antitumor CD8 MHC Class I-Restricted T Cells That Are CytolyticIn Vitroand TumoricidalIn Vivo. Journal of Interferon and Cytokine Research, 1996, 16, 771-776.	1.2	9
117	Vaccine of Engineered Tumor Cells Secreting Stromal Cellâ€“Derived Factor-1 Induces T-Cell Dependent Antitumor Responses. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 401-409.	1.0	9
118	Active CD4⁺helper T cells directly stimulate CD8⁺cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet Î²-cell ovalbumin antigen leading to diabetes. Autoimmunity, 2008, 41, 501-511.	2.6	9
119	LFA-1 defect-induced effector/memory CD8+ T cell apoptosis is mediated via Bcl-2/Caspase pathways and associated with downregulation of CD27 and IL-15R. Molecular Immunology, 2010, 47, 2411-2421.	2.2	9
120	Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-Ï„. Human Antibodies, 1996, 7, 21-26.	1.5	8
121	Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibodyâ€“TAG72 antigen interaction. Protein Engineering, Design and Selection, 1996, 9, 539-543.	2.1	8
122	Significant Tumor Regression Induced by Microencapsulation of Recombinant Tumor Cells Secreting Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 260-266.	1.0	8
123	Transgene IL-6 Enhances DC-Stimulated CTL Responses by Counteracting CD4+25+Foxp3+ Regulatory T Cell Suppression via IL-6-Induced Foxp3 Downregulation. International Journal of Molecular Sciences, 2014, 15, 5508-5521.	4.1	8
124	Activation of Focal Adhesion Kinase Restores Simulated Microgravity-Induced Inhibition of Osteoblast Differentiation via Wnt/Î²-Catenin Pathway. International Journal of Molecular Sciences, 2022, 23, 5593.	4.1	8
125	Differences in antigenâ€binding affinity caused by single amino acid substitution in the variable region of the heavy chain. Immunology and Cell Biology, 1993, 71, 239-247.	2.3	7
126	Production and Characterization of a Tumor-Specific Monoclonal Antibody Act19 Recognizing an Epitope Distinctive from Sialosyl-Tn on the TAG72 Antigen. Tumori, 1993, 79, 58-65.	1.1	7

#	Article	IF	Citations
127	Immunolocalization of hepatic metastases of human colonic cancer by chimeric anti-TAG72 antibody in scid mice. Journal of Surgical Oncology, 1995, 59, 3-9.	1.7	7
128	Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice. Gastroenterology, 1995, 109, 1950-1957.	1.3	7
129	Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Human Antibodies, 1996, 7, 2-10.	1.5	7
130	Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding. Protein Engineering, Design and Selection, 1999, 12, 417-421.	2.1	7
131	The Energy Sensor AMPKÎ±1 Is Critical in Rapamycin-Inhibition of mTORC1-S6K-Induced T-cell Memory. International Journal of Molecular Sciences, 2022, 23, 37.	4.1	7
132	Prosurvival IL-7â€“Stimulated Weak Strength of mTORC1-S6K Controls T Cell Memory via Transcriptional FOXO1â€“TCF1â€“Id3 and Metabolic AMPKÎ±1â€“ULK1â€“ATG7 Pathways. Journal of Immunology, 2022, 208, 155-168.	0.8	7
133	CD4+ T cell-independent maintenance and expansion of memory CD8+ T cells derived from in vitro dendritic cell activation. International Immunology, 2006, 18, 887-895.	4.0	6
134	Alpha tumor necrosis factor contributes to CD8+ T cell survival in the transition phase. Biochemical and Biophysical Research Communications, 2007, 360, 702-707.	2.1	6
135	T cell precursor frequency differentially affects CTL responses under different immune conditions. Biochemical and Biophysical Research Communications, 2008, 367, 427-434.	2.1	6
136	Potent immunotherapy against wellâ€established thymoma using adoptively transferred transgene ILâ€6â€engineered dendritic cellâ€stimulated CD8⁺ Tâ€cells with prolonged survival and enhanced cytotoxicity. Journal of Gene Medicine, 2015, 17, 153-160.	2.8	6
137	CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection. Biochemical and Biophysical Research Communications, 2017, 484, 662-667.	2.1	6
138	Enzyme-linked immunosorbent assay-based selection and optimization of elution buffer for TAG72-affinity chromatography. Biomedical Applications, 1999, 731, 299-308.	1.7	5
139	Dendritic Cell/Myeloma Hybrid Vaccine. , 2005, 113, 225-234.		5
140	Tumor-derived HLA-G1 acquisition by monocytes through trogocytosis: possible functional consequences. Cellular and Molecular Life Sciences, 2010, 67, 4107-4108.	5.4	5
141	Enhanced therapeutic efficacy of adenovirus-mediated interleukin-24 gene therapy combined with ionizing radiotherapy for nasopharyngeal carcinoma. Oncology Reports, 2013, 30, 1165-1174.	2.6	5
142	Enhanced Protective Immunity Derived from Dendritic Cells with Phagocytosis of CD40 Ligand Transgene-engineered Apoptotic Tumor Cells via Increased Dendritic Cell Maturation. Tumori, 2015, 101, 637-643.	1.1	5
143	Innate and Adoptive Immune Cells Contribute to Natural Resistance to Systemic Metastasis of B16 Melanoma. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 72-78.	1.0	5
144	Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth. Cancer Gene Therapy, 2000, 7, 37-44.	4.6	4

#	Article	IF	Citations
145	A new dynamic model of three cell interactions for CTL responses. OncoImmunology, 2012, 1, 1430-1432.	4.6	4
146	Novel T-cell-based vaccines via arming polyclonal CD4⁺ T cells with antigen-specific exosomes. Immunotherapy, 2016, 8, 1265-1269.	2.0	4
147	An In Vitro Experimental Study of the Pulse Delivery Method in Irreversible Electroporation. Journal of Engineering and Science in Medical Diagnostics and Therapy, 2018, 1, .	0.5	4
148	High-affinity chimeric anti-(colorectal carcinoma) antibody correlated to enhanced tumor targeting in biodistribution and imaging. Journal of Cancer Research and Clinical Oncology, 1993, 120, 57-62.	2.5	3
149	Substitution of Surface-Exposed Framework Residues Alters Secretion of Recombinant Fusion Protein Fv/Tumor Necrosis Factor in Escherichia coli. IUBMB Life, 1999, 48, 327-332.	3.4	3
150	Substitution of Surfaceâ€Exposed Framework Residues Alters Secretion of Recombinant Fusion Protein Fv/Tumor Necrosis Factor in Escherichia coli. IUBMB Life, 1999, 48, 327-332.	3.4	3
151	Conversion of Tolerogenic CD4Â¯8Â¯ Dendritic Cells to Immunogenic Ones Inducing Efficient Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 74-80.	1.0	3
152	High Binding Affinity Chimeric Anti-Colorectal Carcinoma Antibody Correlated to Enhanced Tumor Binding and Effector Function. Cancer Biotherapy, 1993, 8, 171-180.	0.5	2
153	Cloning and Expression of Functional cDNA Genes of a Mouse/Human Chimeric Antibody rcM4. Tumori, 1994, 80, 473-479.	1.1	2
154	Molecular and Immunophenotypical Characterization of Progressive and Regressive Leukemia Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 290-299.	1.0	2
155	The Tyrosine Residue at Position 97 in the V_HCDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen. Cancer Biotherapy, 1993, 8, 253-262.	0.5	1
156	Antitumor Vaccination with Gene-Transduced Tumor Cells Expressing a Fusion Protein RM4/IFN-Ï„. Cancer Biotherapy and Radiopharmaceuticals, 1997, 12, 123-130.	1.0	1
157	Genetic Engineering of a Recombinant Fusion Protein Possessing an Antitumor Antibody Fragment and a TNF-Î± Moiety. , 2003, 215, 201-212.		1
158	A Critical Role of FAK/Rhoa Signaling in Simulated Microgravity-Altered Cell Apoptosis, Proliferation and Metastasis. Journal of Cell Signaling, 2018, 03, .	0.3	1
159	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. , 0, .		1
160	Genetic Engineering of Dendritic Cells by Adenovirus-Mediated TNF-Î± Gene Transfer. , 2003, 215, 213-226.		1
161	A genetically engineered single-gene-encoded anti-TAG72 chimeric antibody secreted from myeloma cells. Human Antibodies, 1995, 6, 161-166.	1.5	0
162	Radioimmunoscintigraphy of Gastric Adenocarcinomas with 99mTc-Chimeric ccM4 Antibody. Cancer Biotherapy and Radiopharmaceuticals, 1996, 11, 125-131.	1.0	0

#	Article	IF	Citations
163	Study of B72.3 combining sites by molecular modeling and site-directed mutagenesis. Protein Engineering, Design and Selection, 2000, 13, 339-344.	2.1	0
164	CD8⁺ memory T-cell inflation renders compromised CD4⁺ T-cell-dependent CD8⁺ T-cell immunity via naïve T-cell anergy. ImmunoTargets and Therapy, 2017, Volume 6, 39-49.	5.8	0
165	TLR ligands efficiently convert tolerogenic CD4â€8â€•DC into immunogenic ones stimulating longâ€lasting antitumor immune response. FASEB Journal, 2008, 22, 1068.18.	0.5	0
166	The Tat Protein Enhances CTL Responses and Therapeutic Immunity of Gag-Specific Exosome-Targeted T Cell-Based Gag/Tat-Texo Vaccine in Transgenic HLA-A2 Mice. World Journal of Vaccines, 2017, 07, 11-25.	0.8	0